hosts, such as solid organ transplant recipients, the use of corticosteroids and immunosuppressive drugs, which are known risk factors in these recipients, contribute to the development of overwhelming infection (hyperinfection and disseminated disease), which may lead to death. Infection in these recipients may be due to the reactivation of latent infection in the recipient or transmission from the donor organ, both of which can be prevented when pre-transplant screening practices are employed.
In 2013, American Society of Transplantation (AST) provided guidelines recommending that evaluation for Strongyloides infection be strongly considered in transplant candidates and donors with epidemiologic risk factors or unexplained eosinophilia. 4 From 2009 to 2013, CDC conducted investigations of 7 clusters of donor-derived strongyloidiasis involving 11 infected recipients, 2 of whom died from overwhelming infection. Donor screening was not performed prior to organ transplantation in any of these investigations. 5 In contrast, 
| ME THODS
A survey to assess the screening practices of OPOs was conducted Seattle, WA) and SAS 9.4 (SAS Institute, Inc.; Cary, NC).
The survey was reviewed in accordance with CDC human subjects review procedures and was determined to be a non-research, program evaluation activity. 
| RE SULTS

| Screening strategies, rationale, and results
All 58 US
ABANYIE Et Al. for screening. Four of the 6 OPOs reported using a commercial laboratory for testing, including Viracor, VRL, and Quest Diagnostics
| Considerations around implementing screening in the future
Among OPOs that do not currently screen for Strongyloides (n = 52), 31 (60%) have not considered screening, 6 (11%) considered screening and decided not to screen, 13 (25%) considered screening and
have not yet come to a decision, and 1 (2%) has considered screening and has plans to start in the near future; 1 OPO did not respond to 
| D ISCUSS I ON
The majority of US OPOs are currently not screening donors for that have a sensitivity ranging from 84% to 95% and a specificity ranging from 82% to 100%, depending on the specific laboratory assay used. The turnaround time ranges from 1 to 10 days; 1 OPO reported a cost of $70 per test when using a laboratory affiliated with an academic institution. In addition, the CDC provides confirmatory testing using a crude antigen (CrAg) ELISA with a sensitivity of 96% and a specificity of 98%. In addition, continued effort is needed to educate OPOs that have not considered screening for strongyloidiasis. These OPOs serve almost 60% of the population covered by the 58 OPOs and are critical to improving transplant safety for the nation.
ACK N OWLED G EM ENTS
The 
